Nuvation Bio Inc. Enters Material Agreement, Incurs Financial Obligation
Ticker: NUVB · Form: 8-K · Filed: Mar 4, 2025 · CIK: 1811063
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
Nuvation Bio just signed a big deal and owes money.
AI Summary
On March 3, 2025, Nuvation Bio Inc. entered into a material definitive agreement and created a direct financial obligation. The company, formerly known as Panacea Acquisition Corp., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing indicates Nuvation Bio Inc. has entered into a significant agreement that creates a financial obligation, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements and incurring financial obligations can introduce financial risks and operational changes for the company.
Key Players & Entities
- Nuvation Bio Inc. (company) — Registrant
- Panacea Acquisition Corp. (company) — Former company name
- March 3, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
FAQ
What type of material definitive agreement did Nuvation Bio Inc. enter into?
The filing states that Nuvation Bio Inc. entered into a 'Material Definitive Agreement' but does not specify the exact nature of the agreement in the provided text.
What is the nature of the direct financial obligation incurred by Nuvation Bio Inc.?
The filing indicates the creation of a 'Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement' but does not detail the specific obligation in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on March 3, 2025.
What was Nuvation Bio Inc. formerly known as?
Nuvation Bio Inc. was formerly known as Panacea Acquisition Corp.
In which state is Nuvation Bio Inc. incorporated?
Nuvation Bio Inc. is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 4, 2025 regarding Nuvation Bio Inc. (NUVB).